UnitedHealth
UnitedHealth Group is a leading American healthcare company operating through two major businesses: UnitedHealthcare, which provides health insurance and medical benefit plans for individuals, employers and government programmes, and Optum, which delivers healthcare services, pharmacy benefits, data analytics and technology solutions. UnitedHealthcare is its health insurance business, while Optum is the part driving its healthcare services, pharmacy and technology operations.
UnitedHealth Group 是美国领先的医疗保健公司,主要通过两大业务运营:UnitedHealthcare 提供个人、企业及政府医疗保险和医疗福利计划;Optum 则提供医疗服务、药房福利、数据分析及科技解决方案。UnitedHealthcare 是公司的医疗保险核心业务,而 Optum 则推动其医疗服务、药房及医疗科技业务的发展。
The forecast figures are tipranks’s, read on 2026-11-16 and linked below.
SmartChecker UnitedHealth Forecast
The forecast in short
tipranks records 17 analyst ratings on UnitedHealth and summarises them as “Strong Buy”. Their average 12-month price target is USD 482.69 (18.46% Upside). Its tipranks score is 7 out of 10 — Neutral. These are tipranks’s figures as SmartChecker read them on 2026-11-16, not SmartChecker’s own view, and nothing here is advice to buy or sell.
Market cap
USD 365.09 B
≈ RM 1.49T
Share price
USD 407.46
≈ RM 1,667.08
#39World ranking
tipranks score
Neutral
Analyst ratings
Strong Buy
- Buy14 82%
- Hold3 18%
- Sell0 0%
tipranks’s own summary of the 17 ratings above.
12 months price forecast
USD 482.69 18.46% Upside
As tipranks publishes it. SmartChecker has not recalculated any of it.
Analyst profiles. Who made each call, and when.
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Elizabeth Anderson CFA | Evercore ISI | Buy | USD 480 | 2026-11-10 |
| Lance Wilkes | Bernstein | Buy | USD 500 | 2026-11-04 |
| Stephen Baxter | Wells Fargo | Buy | USD 487 | 2026-10-27 |
| Erin Wright | Morgan Stanley | Buy | USD 531 | 2026-10-27 |
| Ann Hynes | Mizuho Securities | Buy | USD 500 | 2026-10-22 |
| Ben Hendrix | RBC Capital | Buy | USD 498 | 2026-10-19 |
| Lisa Gill | J.P. Morgan | Buy | USD 524 | 2026-10-16 |
| Whit Mayo | Leerink Partners | Buy | USD 472 | 2026-10-15 |
| Ryan Langston | TD Cowen | Hold | USD 402 | 2026-10-15 |
| Parker Snure | Raymond James | Buy | USD 450 | 2026-10-15 |
| Andrew Mok CFA | Barclays | Buy | USD 440 | 2026-10-14 |
| Kevin Fischbeck | Bank of America Securities | Buy | USD 512 | 2026-10-14 |
| Jessica Tassan | Piper Sandler | Buy | USD 504 | 2026-10-14 |
| Michael Ha | Robert W. Baird | Hold | USD 427 | 2026-10-14 |
| Scott Fidel | Goldman Sachs | Buy | USD 506 | 2026-10-13 |
| A.J. Rice | UBS | Buy | USD 490 | 2026-10-12 |
| Hans Engel | Erste Group | Hold | N/A | 2026-10-08 |
| George Hill | Deutsche Bank | Hold | N/A | 2026-08-03 |
| David S Macdonald | Truist Financial | Buy | USD 500 | 2026-07-17 |
| Michael Wiederhorn | Oppenheimer | Buy | USD 500 | 2026-07-17 |
| David Toung | Argus Research | Buy | USD 470 | 2026-07-17 |
| Matthew Gillmor CFA | KeyBanc | Buy | USD 475 | 2026-07-14 |
| Sidharth Sahoo | HSBC | Hold | USD 380 | 2026-07-06 |
| David Windley | Jefferies | Buy | USD 373 | 2026-04-20 |
| Sarah James | Cantor Fitzgerald | Buy | USD 440 | 2026-01-28 |
Show moreShow less
Investment Strengths
Strong cash generation强劲的现金创造能力
UnitedHealth’s substantial operating and free cash flow supports investment across insurance, pharmacy, care delivery, and technology services while funding dividends and other capital needs. Free cash flow has also generally tracked earnings well, indicating meaningful underlying cash conversion despite recent growth volatility.UnitedHealth 强劲的经营现金流和自由现金流,为保险、药品服务、医疗服务及科技业务的持续投资提供了充足资金,同时也能够支持股息支付及其他资本需求。自由现金流整体上与盈利表现保持较好的同步性,反映出公司具备扎实的现金转化能力,即使近期业务增长出现波动,仍展现出一定的财务韧性。
Diversified healthcare platform多元化医疗保健业务平台
The combination of UnitedHealthcare and Optum gives UnitedHealth multiple revenue streams across the healthcare value chain, reducing reliance on any single product or customer category. Its scale across benefits, pharmacy, care, and data services can support cross-segment capabilities and sustained relevance.UnitedHealthcare 与 Optum 两大业务板块的结合,使 UnitedHealth 能够在整个医疗保健价值链中建立多元化收入来源,降低对单一产品或客户类别的依赖。公司在医疗保险福利、药品服务、医疗护理及数据服务领域的规模优势,有助于推动不同业务板块之间的协同效应,并巩固其在医疗保健行业中的长期竞争地位。
Medicare and Optum improvementMedicare 与 Optum 业务改善
Improving Medicare margins and Optum Health’s large patient base provide identifiable avenues for earnings recovery and expansion. Progress toward the stated Optum margin range, together with value-based care and post-acute opportunities, could strengthen profitability over multiple quarters.Medicare 利润率的改善,以及 Optum Health 庞大的患者基础,为公司未来盈利复苏及业务扩张提供了明确的发展机会。随着公司逐步实现既定的 Optum 利润率目标区间,并持续拓展价值导向医疗(Value-Based Care)及急性后期护理(Post-Acute Care)业务,有望在未来多个季度进一步提升整体盈利能力。
People also ask
What is the 12-month price target for UnitedHealth (UNH)?
tipranks publishes an average 12-month price target of USD 482.69 (18.46% Upside), as SmartChecker read it on 2026-11-16. The highest target is USD 531 and the lowest is USD 402. A price target is an analyst’s estimate of where a share might trade, not a promise, and SmartChecker gives no investment advice.
See tipranks’s own page ↗How many analysts cover UnitedHealth (UNH)?
tipranks records 17 analyst ratings: 14 buy, 3 hold and 0 sell, which it summarises as “Strong Buy”, as SmartChecker read it on 2026-11-16.
See tipranks’s own page ↗What is the tipranks score for UnitedHealth (UNH)?
tipranks scores it 7 out of 10 and calls that “Neutral”, as SmartChecker read it on 2026-11-16. The score is tipranks’s, not SmartChecker’s, and SmartChecker does not rate listed shares.
See tipranks’s own page ↗Is this SmartChecker’s own forecast for UnitedHealth?
No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. SmartChecker assesses financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.
See tipranks’s own page ↗Member reviews. Members’ own ratings and words, not SmartChecker’s rating.
These ratings and words are written by SmartChecker members and published immediately without administrator approval. SmartChecker does not rate listed companies: a rating here belongs to whoever wrote it, it counts towards no score of ours, and nothing in it is advice.
Disclaimer
SmartChecker provides informational and financial market news only and does not provide investment, financial or legal advice.
